Monoclonal antibody as therapy for malignant lymphomas

被引：43
作者：
Coiffier, B
机构：
[1] Hospices Civils Lyon, Serv Hematol, F-69495 Pierre Benite, France
[2] Univ Lyon 1, F-69495 Pierre Benite, France
来源：
COMPTES RENDUS BIOLOGIES | 2006年 / 329卷 / 04期
关键词：
rituximab; R-CHOP; follicular lymphoma; diffuse large B-cell lymphoma; radio-labelled antibodies; monoclonal antibodies;
D O I：
10.1016/j.crvi.2005.12.006
中图分类号：
Q [生物科学];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
Rituximab was the first monoclonal antibody to have been registered for the treatment of B-cell lymphomas. Randomized studies have demonstrated its activity in follicular lymphoma, mantle-cell lymphoma, and diffuse large B-cell lymphoma in untreated or relapsing patients. Because of its high activity and low toxicity ratio, rituximab has transformed the outcome of patients with B-cell lymphoma. A combination of rituximab plus chemotherapy, R-CHOP has the highest efficacy ever described with any chemotherapy in diffuse large B-cell lymphoma and follicular lymphoma. The role of radio-labelled antibodies is still to be defined.
引用
收藏
页码：241 / 254
页数：14
相关论文
共 87 条
[1]   Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial [J].
Ardeshna, KM ;
Smith, P ;
Norton, A ;
Hancock, BW ;
Hoskin, PJ ;
MacLennan, KA ;
Marcus, RE ;
Jelliffe, A ;
Hudson, GV ;
Linch, DC .
LANCET, 2003, 362 (9383) :516-522
[2]   Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma:: a single institution study [J].
Belhadj, K ;
Delfau-Larue, MH ;
Elgnaoui, T ;
Beaujean, F ;
Beaumont, JL ;
Pautas, C ;
Gaillard, I ;
Kirova, Y ;
Allain, A ;
Gaulard, P ;
Farcet, JP ;
Reyes, F ;
Haioun, C .
ANNALS OF ONCOLOGY, 2004, 15 (03) :504-510
[3]   Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma [J].
Berinstein, NL ;
Grillo-Lopez, AJ ;
White, CA ;
Bence-Bruckler, I ;
Maloney, D ;
Czuczman, M ;
Green, D ;
Rosenberg, J ;
McLaughlin, P ;
Shen, D .
ANNALS OF ONCOLOGY, 1998, 9 (09) :995-1001
[4]  
Bienvenu J, 2001, Hematol J, V2, P378, DOI 10.1038/sj.thj.6200133
[5]   Evidence for Fcγ receptor IIIA-independent rituximab effector mechanisms in patients with follicular lymphoma treated with combined immuno-chemotherapy. [J].
Boettcher, S ;
Pott, C ;
Ritgen, M ;
Hiddemann, W ;
Unterhalt, M ;
Kneba, M .
BLOOD, 2004, 104 (11) :170A-171A
[6]   Variation in gene expression patterns in follicular lymphoma and the response to rituximab [J].
Bohen, SP ;
Troyanskaya, OG ;
Alter, O ;
Warnke, R ;
Botstein, D ;
Brown, PO ;
Levy, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (04) :1926-1930
[7]   Clearing minimal residual disease with rituximab consolidation therapy [J].
Brugger, W .
SEMINARS IN ONCOLOGY, 2004, 31 (01) :33-37
[8]   Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712) [J].
Byrd, JC ;
Peterson, BL ;
Morrison, VA ;
Park, K ;
Jacobson, R ;
Hoke, E ;
Vardiman, JW ;
Rai, K ;
Schiffer, CA ;
Larson, RA .
BLOOD, 2003, 101 (01) :6-14
[9]   Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011 [J].
Byrd, JC ;
Rai, K ;
Peterson, BL ;
Appelbaum, FR ;
Morrison, VA ;
Kolitz, JE ;
Shepherd, L ;
Hines, JD ;
Schiffer, CA ;
Larson, RA .
BLOOD, 2005, 105 (01) :49-53
[10]   Rituximab using a thrice weekly dosing schedule in B-Cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity [J].
Byrd, JC ;
Murphy, T ;
Howard, RS ;
Lucas, MS ;
Goodrich, A ;
Park, K ;
Pearson, M ;
Waselenko, JK ;
Ling, G ;
Grever, MR ;
Grillo-Lopez, AJ ;
Rosenberg, J ;
Kunkel, L ;
Flinn, IW .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) :2153-2164
123456789